177Lu-DOTA-Miltuximab

**177Lu-DOTA-Miltuximab** is a radiopharmaceutical drug under development for the treatment of cancer, particularly targeting tumors that express Glypican-1. It consists of the monoclonal antibody Miltuximab conjugated to the chelator DOTA and radiolabeled with the beta-emitting isotope Lutetium‑177. The mechanism of action involves targeted delivery of ionizing radiation to tumor cells via binding to Glypican‑1, leading to localized cell death. Preclinical and early clinical studies have shown promising safety and efficacy in prostate cancer models, with ongoing trials in other cancers such as pancreatic and urothelial carcinoma. The drug is being developed by GlyTherix[1][2][3][4][5].

Other names

177Lu-DOTA-Miltuximablutetium-177 chloride Miltuximablutetium177 chloride Miltuximablutetium 177 chloride MiltuximabLutetium-177 DOTA antibodyLutetium177 DOTA antibodyLutetium 177 DOTA antibody